Phenylketonuria Drug Sales

Pheynylketonuria Drug Sales Market Outlook

The global phenylketonuria (PKU) drug sales market is projected to reach approximately USD 1.8 billion by 2035, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035. This growth can be attributed to the increasing prevalence of phenylketonuria, a metabolic disorder that requires lifelong dietary management and medical treatment. The rise in awareness regarding PKU, advancements in drug formulations, and the growing number of healthcare facilities specializing in metabolic disorders are significant factors propelling the market. Furthermore, the expansion of telemedicine and remote health monitoring solutions has also facilitated patient access to specialized PKU treatments, thereby contributing to market growth. The innovative approaches in drug development and the emergence of new therapies are anticipated to foster additional growth opportunities within the market.

Growth Factor of the Market

One of the primary growth factors for the phenylketonuria drug sales market is the increasing global prevalence of PKU, which is estimated to affect around 1 in 10,000 to 15,000 live births. This statistical rise necessitates the availability of effective treatments and management options, driving demand for PKU-related drugs. Additionally, heightened awareness regarding genetic disorders and the importance of early diagnosis through newborn screening programs have significantly contributed to the market's expansion. Improved healthcare infrastructure and access to specialty pharmacies have also enhanced the availability of PKU medications, further stimulating market growth. Furthermore, the development of novel pharmacological therapies and dietary supplements aimed at managing PKU presents lucrative opportunities for market players. The integration of advanced technologies in drug delivery systems is also expected to play a crucial role in transforming treatment modalities for PKU.

Key Highlights of the Market

• Projected market size of approximately USD 1.8 billion by 2035.
• CAGR of 7.2% from 2025 to 2035, indicating robust growth.
• Rising prevalence of PKU driving demand for innovative treatment options.
• Increased awareness and early diagnosis through newborn screening programs.
• Advancements in drug formulations and delivery methods enhancing treatment efficacy.

By Product Type

Oral Medications:

Oral medications are a significant segment in the phenylketonuria drug sales market as they offer a user-friendly and convenient means of administration for patients. These medications typically include formulations that help in reducing phenylalanine levels in the bloodstream, allowing individuals with PKU to manage their condition effectively. The ease of swallowing capsules or tablets makes oral medications particularly appealing for pediatric patients and adults alike. Furthermore, advancements in taste-masking technologies and flavoring agents have improved the palatability of these medications, increasing patient adherence to treatment regimens. As awareness of PKU continues to grow, the demand for oral medications is expected to rise, ultimately contributing to the overall growth of this market segment.

Injectable Medications:

Injectable medications play a crucial role in the management of phenylketonuria, particularly for patients who may experience difficulty in adhering to oral therapies. These medications often provide a more rapid and effective means of lowering phenylalanine levels in the blood, making them a vital option for acute management scenarios. The segment includes biologics and other therapeutic agents that are administered subcutaneously or intravenously, ensuring precise dosing and immediate effects. As the PKU landscape evolves, the prevalence of new injectable therapies is increasing, with more innovative treatment options entering the market. This surge in injectable formulations is expected to attract significant attention from healthcare practitioners and patients, consequently driving sales in this segment.

Supplements:

Dietary supplements have emerged as an essential component of the treatment strategy for individuals with phenylketonuria. These supplements are designed to provide essential nutrients that are typically restricted in a standard PKU diet, ensuring that patients receive adequate vitamins and minerals despite their limited intake of certain food types. The market for PKU supplements is expanding, driven by increasing awareness among patients about the importance of maintaining nutritional balance while adhering to a low-phenylalanine diet. Moreover, the growing trend towards personalized nutrition and dietary management further fuels demand for tailored supplements that cater specifically to the needs of PKU patients. As more companies enter this niche market with innovative supplement formulations, the segment is poised for significant growth.

Formula:

Specialized formulas are a cornerstone of dietary management for individuals diagnosed with phenylketonuria, as they provide a controlled source of protein and are essential in ensuring nutritional adequacy. These formulas are specifically designed to be low in phenylalanine while offering a balanced mix of other nutrients required for growth and development, especially in infants and children. The demand for PKU-specific formulas has been steadily increasing, primarily due to heightened awareness of the dietary needs of PKU patients. Advances in formula technology have led to improved taste and texture, making these products more appealing to consumers. As healthcare providers and nutritionists continue to emphasize the importance of tailored dietary interventions in managing PKU, the formula segment is expected to witness substantial growth in the foreseeable future.

By Application

Hospitals:

Hospitals represent a significant application segment for phenylketonuria drugs, as they serve as the primary healthcare settings for diagnosing and managing metabolic disorders. In hospitals, a multidisciplinary approach is often employed, involving pediatricians, dietitians, and metabolic specialists to ensure comprehensive care for PKU patients. The presence of specialized clinics within hospitals allows for targeted therapeutic interventions and monitoring of treatment efficacy. Furthermore, hospitals often stock a wide range of PKU medications and dietary supplements, ensuring that patients have access to essential treatments during their hospital stays or outpatient visits. With the increasing focus on early diagnosis and prompt treatment of PKU, hospitals are expected to remain a key driver of sales in this market segment.

Clinics:

Clinics focused on metabolic disorders are crucial in the management of phenylketonuria, providing specialized care and tailored treatment plans for patients. These clinics often offer comprehensive services, including nutritional counseling, regular monitoring of phenylalanine levels, and access to a wide variety of PKU medications and supplements. The personalized approach taken by these clinics ensures that patients receive suitable interventions according to their individual needs, resulting in better health outcomes. The rise in PKU awareness and the growing number of specialized clinics across various regions are likely to enhance the segment's contribution to the overall drug sales market. Additionally, collaborations between clinics and pharmaceutical companies to create educational programs and support services can further stimulate growth in this segment.

Retail Pharmacies:

Retail pharmacies serve as an essential distribution channel for phenylketonuria drugs, providing patients with convenient access to their necessary medications and dietary supplements. These pharmacies typically stock a range of PKU products, including oral medications, supplements, and specialized formulas, making it easier for patients to obtain their treatments without the need for hospital visits. The increasing prevalence of PKU, coupled with the growing trend towards self-management of health conditions, has led to a rising demand for retail pharmacy services specifically tailored to the needs of PKU patients. Furthermore, the integration of telepharmacy services and online ordering options is enhancing accessibility for patients, particularly in rural or underserved areas. As patient preferences evolve, retail pharmacies are expected to play an increasingly vital role in the phenylketonuria drug sales market.

Online Pharmacies:

Online pharmacies have emerged as a pivotal avenue for accessing phenylketonuria medications and supplements, particularly in today's digital age where convenience and accessibility are paramount. These platforms enable patients to order their necessary treatments from the comfort of their homes, often with the added benefit of discreet packaging and home delivery services. The growing trend of e-commerce, alongside the increasing comfort of consumers with online shopping, has led to surging sales of PKU products through digital channels. Moreover, online pharmacies often provide competitive pricing and access to a broader range of products compared to traditional brick-and-mortar pharmacies, further attracting customers. As more patients seek flexible options for managing their PKU treatments, the online pharmacy segment is projected to witness significant growth in the coming years.

By Distribution Channel

Prescription-Based:

The prescription-based distribution channel is vital for the phenylketonuria drug sales market, as it ensures that patients receive medications specifically tailored to their treatment needs following a healthcare provider's evaluation. Prescription medications are critical for managing PKU, particularly due to the need for continuous monitoring of phenylalanine levels and adjustments in therapy as patients grow or their conditions change. Healthcare professionals often play an essential role in educating patients about the importance of adhering to prescribed treatments, which can involve oral medications, injectable therapies, and dietary supplements. The regulatory framework surrounding prescription medications further enhances patient safety and efficacy, making this channel a cornerstone of the PKU drug market. As the healthcare landscape shifts towards improved patient outcomes and personalized care, the prescription-based channel will likely continue to dominate sales in this segment.

Over-the-Counter:

The over-the-counter (OTC) distribution channel is increasingly gaining traction in the phenylketonuria drug sales market, particularly for dietary supplements and certain formulation products that do not require a prescription. OTC products are often more accessible, allowing patients to manage their PKU treatments without the need for a formal consultation with a healthcare provider. This convenience appeals to many patients and caregivers who seek to supplement their dietary management with additional nutrients or therapeutic agents. The growing awareness of PKU and the importance of nutritional support has led to a rise in the availability of OTC supplements and formulas specifically designed for PKU patients. As consumer preferences shift towards self-managed health solutions, the OTC segment is expected to experience significant growth, complementing the prescription-based approach to PKU management.

By Ingredient Type

Sapropterin:

Sapropterin is a key ingredient in the phenylketonuria drug sales market, functioning as a pharmacological agent designed to lower blood phenylalanine levels. This medication is particularly significant for patients with BH4-responsive PKU, as it enhances the enzyme's ability to metabolize phenylalanine, thereby allowing for increased dietary intake of protein without compromising health. The introduction of sapropterin has revolutionized PKU treatment options, providing patients with greater flexibility in dietary management. As clinical guidelines evolve and highlight the benefits of sapropterin, its adoption is expected to increase among healthcare providers and patients. Consequently, this ingredient segment is projected to play a crucial role in driving growth within the overall PKU drug market.

Phenylalanine:

Phenylalanine, while being a restricted amino acid for individuals with PKU, is a critical focus in the development of treatments aimed at managing dietary intake. Specialized formulas and medications are designed to be low in phenylalanine, ensuring that patients can maintain nutritional balance while adhering to their treatment regimens. The market for phenylalanine-related products is expanding, driven by the demand for alternatives that allow for adequate protein consumption without elevating blood phenylalanine levels. As the understanding of dietary management in PKU progresses, the development of innovative products that strategically incorporate phenylalanine will further stimulate growth in this segment. The focus on tailored solutions that support the dietary needs of PKU patients is expected to enhance the market for phenylalanine-based treatments.

Tetrahydrobiopterin:

Tetrahydrobiopterin (BH4) serves as a cofactor in the enzymatic conversion of phenylalanine to tyrosine, making it an essential ingredient in the treatment of phenylketonuria. For patients with PKU who are responsive to BH4, the administration of this compound can significantly improve metabolic control and allow for greater dietary freedom. The use of tetrahydrobiopterin is increasingly recognized in clinical practice, as it provides a unique therapeutic approach to managing elevated phenylalanine levels. As research continues to demonstrate the efficacy of BH4 in various patient populations, the demand for tetrahydrobiopterin as a treatment option is anticipated to grow substantially. This segment is likely to represent a significant portion of the overall PKU drug market as awareness and utilization increase.

Others:

The "Others" category encompasses a range of additional ingredients and formulations used in the management of phenylketonuria. This may include alternative amino acid formulations and specialized dietary products designed to support individuals with PKU in their daily nutritional intake. These products are gaining traction due to the growing recognition of the importance of tailored dietary interventions for managing PKU effectively. As more companies innovate and develop novel ingredients that cater to the specific needs of PKU patients, the "Others" segment is expected to expand significantly. The diverse array of offerings in this category allows for a more personalized approach to PKU treatment, ensuring that patients have access to a variety of options that align with their dietary preferences and health goals.

By Region

In terms of regional analysis, North America holds a leading position in the phenylketonuria drug sales market, accounting for approximately 45% of the total market share. The region's dominance can be attributed to its well-established healthcare infrastructure, high levels of awareness regarding metabolic disorders, and the availability of advanced treatment options. The presence of leading pharmaceutical companies and specialized clinics has facilitated the development and distribution of effective PKU medications. Furthermore, initiatives to promote newborn screening for PKU have significantly contributed to early diagnosis and treatment, fostering a favorable environment for market growth. The North American market is expected to continue expanding at a CAGR of 6.5% through 2035, driven by ongoing advancements in treatment methodologies.

Europe is experiencing a robust growth trajectory in the phenylketonuria drug sales market, accounting for around 30% of the global market share. The region benefits from a supportive regulatory framework that encourages innovation and accessibility to PKU medications. The increasing prevalence of PKU diagnoses and the emphasis on early intervention through newborn screening programs are positively impacting the market. Additionally, collaborations between pharmaceutical companies and healthcare institutions to enhance patient education and support services have further stimulated growth within this region. As European healthcare systems continue to prioritize metabolic health, the PKU drug sales market is projected to witness a steady rise in demand for specialized treatments and dietary products.

Opportunities

The phenylketonuria drug sales market presents numerous opportunities for growth, particularly in the realm of product innovation and the development of personalized treatment strategies. As research advances, new pharmacological therapies and dietary supplements tailored specifically for PKU patients are emerging, providing pivotal alternatives to existing treatment options. Companies that invest in research and development to create novel formulations that cater to the diverse needs of PKU patients are likely to capture significant market share. Additionally, the integration of technology in treatment delivery, such as mobile health applications that facilitate monitoring and adherence, offers an exciting opportunity to enhance patient engagement and improve health outcomes. The potential for telemedicine to facilitate access to specialized care for PKU patients, particularly in remote areas, further underscores the opportunities available in this market.

Moreover, as awareness of phenylketonuria continues to grow, there is an increasing demand for educational programs aimed at patients, families, and healthcare providers. Initiatives that focus on raising awareness about PKU and its management can foster a more informed patient population, ultimately leading to better health outcomes and higher adherence rates to treatment regimens. Collaborations between pharmaceutical companies, healthcare professionals, and advocacy organizations can play a significant role in enhancing education and support networks for individuals affected by PKU. By leveraging these partnerships, organizations can develop comprehensive strategies to address the unique challenges of managing PKU, creating a positive impact on the overall market landscape.

Threats

Despite the promising prospects within the phenylketonuria drug sales market, several threats could potentially hinder growth. One of the predominant concerns is the high cost associated with PKU treatments and specialized dietary products. The prohibitive expense of medications, coupled with limited insurance coverage for some therapies, may pose significant barriers to access for patients. Furthermore, economic fluctuations and changes in healthcare policies can impact reimbursement rates, affecting the affordability of necessary treatments. If patients are unable to access the medications and dietary supplements they require, this could lead to adverse health outcomes and reduced market growth. Additionally, the emergence of alternative treatments and competing products can create challenges for market players, necessitating ongoing innovation to maintain a competitive edge.

Another threat to the phenylketonuria drug sales market is the complexity of managing patient adherence to long-term treatment regimens. Individuals with PKU often face challenges in adhering to strict dietary restrictions and medication schedules, which can complicate their health management. Non-adherence may result from various factors, including the complexity of treatment protocols, dietary limitations, and lack of support from healthcare providers. Consequently, addressing patient adherence is crucial for ensuring the effectiveness of PKU treatments. Failure to provide adequate education, support systems, and counseling can lead to increased morbidity among patients, ultimately impacting the overall market dynamics. As patients seek solutions that cater to their individual needs, companies must focus on developing comprehensive support mechanisms alongside their products to enhance adherence and foster positive health outcomes.

Competitor Outlook

• Merck & Co., Inc.
• BioMarin Pharmaceutical Inc.
• Applied Pharma Research S.A.
• Horizon Therapeutics plc
• Nestlé Health Science
• Regenesis Biomedical, Inc.
• Janssen Pharmaceuticals, Inc.
• Nutricia North America, LLC
• Ajinomoto Co., Inc.
• Kyn Therapeutics, Inc.
• Synlogic, Inc.
• Sankyo Pharma, Inc.
• Alcyone Therapeutics
• Shire PLC
• EUSA Pharma Inc.

The competitive landscape of the phenylketonuria drug sales market is characterized by the presence of several key players engaged in advancing treatment options for individuals diagnosed with PKU. Pharmaceutical companies are actively investing in research and development to create innovative therapies, dietary products, and formulations aimed at improving patient outcomes. Additionally, collaborations and partnerships among industry stakeholders are becoming increasingly common as companies seek to combine their expertise and resources to address unmet needs in the PKU treatment landscape. The ongoing focus on personalized medicine and tailored treatment approaches is driving competition, prompting companies to enhance their product offerings and expand their market reach.

Leading companies such as BioMarin Pharmaceutical Inc. have been at the forefront of developing targeted therapies for PKU, with their product Sapropterin (Kuvan) recognized as a key treatment option. BioMarin's commitment to extensive research and clinical trials has positioned them as a leader in the PKU drug market. Meanwhile, Horizon Therapeutics plc is gaining recognition for its innovative dietary solutions that cater specifically to the needs of PKU patients. Their focus on nutritional health, combined with a robust portfolio of specialty products, has allowed them to carve a significant niche within the market.

Merck & Co., Inc. and Nutricia North America, LLC are also notable players in the phenylketonuria drug sales market. Merck's extensive experience in pharmaceuticals, paired with ongoing efforts to innovate in metabolic health, positions them well for future growth. Nutricia, specializing in medical nutrition, has developed a range of dietary products and formulas specifically designed for individuals with PKU. This specialization enables them to effectively address the unique dietary needs of patients, further enhancing their competitive standing in the market. As the landscape of PKU treatment continues to evolve, these companies are expected to play pivotal roles in shaping the future of phenylketonuria management.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Shire PLC
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Synlogic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 EUSA Pharma Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Merck & Co., Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Ajinomoto Co., Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sankyo Pharma, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Alcyone Therapeutics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Kyn Therapeutics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Horizon Therapeutics plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Regenesis Biomedical, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Nutricia North America, LLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Applied Pharma Research S.A.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 BioMarin Pharmaceutical Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Nestlé Health Science
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Janssen Pharmaceuticals, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Phenylketonuria Drug Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 Online Pharmacies
  • 6.2 Phenylketonuria Drug Sales Market, By Product Type
    • 6.2.1 Oral Medications
    • 6.2.2 Injectable Medications
    • 6.2.3 Supplements
    • 6.2.4 Formula
  • 6.3 Phenylketonuria Drug Sales Market, By Ingredient Type
    • 6.3.1 Sapropterin
    • 6.3.2 Phenylalanine
    • 6.3.3 Tetrahydrobiopterin
    • 6.3.4 Others
  • 6.4 Phenylketonuria Drug Sales Market, By Distribution Channel
    • 6.4.1 Prescription-Based
    • 6.4.2 Over-the-Counter

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Phenylketonuria Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Phenylketonuria Drug Sales market is categorized based on

By Product Type

• Oral Medications
• Injectable Medications
• Supplements
• Formula

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Distribution Channel

• Prescription-Based
• Over-the-Counter

By Ingredient Type

• Sapropterin
• Phenylalanine
• Tetrahydrobiopterin
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Merck & Co., Inc.
• BioMarin Pharmaceutical Inc.
• Applied Pharma Research S.A.
• Horizon Therapeutics plc
• Nestlé Health Science
• Regenesis Biomedical, Inc.
• Janssen Pharmaceuticals, Inc.
• Nutricia North America, LLC
• Ajinomoto Co., Inc.
• Kyn Therapeutics, Inc.
• Synlogic, Inc.
• Sankyo Pharma, Inc.
• Alcyone Therapeutics
• Shire PLC
• EUSA Pharma Inc.